6 days Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the DipThe Motley Fool
Last year, pharmaceutical giant AbbVie (NYSE: ABBV) lost patent exclusivity for its biggest cash cow, immunology medicine Humira. The drugmaker has rebounded quite nicely since. AbbVie returned to top-line growth in the second quarter, much earlier tha…
AbbVie (ABBV) · Dividend · NYSE
X